C12N 2310/346
Having a combination of backbone and sugar modifications
Official title: having a combination of backbone and sugar modifications
C12N2310/346 (Having a combination of backbone and sugar modifications) appears on 1,344 US grants and 2,559 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,344
- Published applications
- 2,559
- Assignees
- 446
- Inventors
- 1,989
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 9 | 0 |
| 1999 | 43 | 0 |
| 2000 | 71 | 0 |
| 2001 | 57 | 9 |
| 2002 | 64 | 29 |
| 2003 | 31 | 213 |
| 2004 | 24 | 242 |
| 2005 | 23 | 145 |
| 2006 | 15 | 61 |
| 2007 | 16 | 68 |
| 2008 | 17 | 28 |
| 2009 | 20 | 59 |
| 2010 | 35 | 52 |
| 2011 | 43 | 50 |
| 2012 | 42 | 56 |
| 2013 | 34 | 59 |
| 2014 | 46 | 67 |
| 2015 | 50 | 76 |
| 2016 | 50 | 99 |
| 2017 | 67 | 96 |
| 2018 | 53 | 107 |
| 2019 | 55 | 113 |
| 2020 | 78 | 136 |
| 2021 | 68 | 141 |
| 2022 | 88 | 171 |
| 2023 | 63 | 153 |
| 2024 | 66 | 126 |
| 2025 | 66 | 107 |
| 2026 | 38 | 96 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- RNAi constructs and methods for inhibiting LPA expression22 Sep 2026US 12,742,169 B2Amgen Inc.
- Modified guide RNAs15 Sep 2026US 12,735,698 B2Intellia Therapeutics, Inc.
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression1 Sep 2026US 12,723,247 B2Alnylam Pharmaceuticals, Inc.
- Antagonism as a therapy for TDP-43 proteinopathies25 Aug 2026US 12,716,065 B2University of Southern California
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Oligonucleotide compositions and methods thereof1 Oct 2026US 2026/0297573 A1Wave Life Sciences Ltd.
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
- Decoy rna oligonucleotides for inhibiting ythdf224 Sep 2026US 2026/0286355 A1Catchme Rna Therapeutics Ltd.
- Oligonucleotides targeting gal3st124 Sep 2026US 2026/0286364 A1
Most cited
By later US patents
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000
- Hybrid oligonucleotide phosphorothioates427US 5,652,355 AWorcester Foundation for Experimental Biology · 1997
- Oligoribonucleotides for cleaving RNA385US 5,898,031 AIsis Pharmaceuticals, Inc. · 1999
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012